Mycoplasma Infections in Poultry: Vaccination Strategies and Control Programs

Introduction

Avian mycoplasmosis represents a persistent global challenge in commercial poultry production, primarily driven by two pathogenic species: Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) [1, 2, 3]. These cell-wall-deficient bacteria belong to the class Mollicutes and are characterized by their small genome size (0.7–1.0 Mb) and fastidious growth requirements [4, 5]. Infection with MG leads to chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys, whereas MS causes infectious synovitis and eggshell apex abnormalities in layers [6, 7, 8]. Both pathogens impose substantial economic losses through reduced egg production, increased mortality, carcass condemnation at slaughter, and elevated medication costs [9, 10, 11]. This article provides an exhaustive review of the etiology, epidemiology, clinical signs, pathology, diagnostic approaches, vaccination strategies, and integrated control programs for Mycoplasma infections in poultry, with a specific emphasis on the role of the [poultry mycoplasma vaccine] in contemporary disease management. The information is drawn from recent peer-reviewed literature and established veterinary references.

Etiology and Epidemiology

The primary etiological agents are M. gallisepticum, M. synoviae, and to a lesser extent M. meleagridis and M. iowae in turkeys [12, 13, 14]. These bacteria lack a cell wall, rendering them intrinsically resistant to beta-lactam antimicrobials and making them susceptible to environmental desiccation and disinfectants [15, 16]. The genome of MS contains a highly variable vlhA gene, which encodes a hemagglutinin and serves as a target for molecular typing [12, 32]. In a 14-year molecular typing study of MS in Italian poultry, Stefani et al. described a predominance of certain vlhA genotypes in industrial versus backyard flocks [12]. Similarly, Zhang et al. reported a high prevalence of MS in central China with a variety of vlhA genotypes over the period 2021–2023 [32].

Transmission occurs horizontally via direct contact, aerosolized respiratory droplets, and contaminated fomites, as well as vertically through the egg (transovarian transmission) [17, 18]. The latter is particularly important for breeder flocks, as infected progeny hatch with subclinical infection that can later be triggered by stressors such as vaccination (e.g., infectious bronchitis virus or Newcastle disease virus vaccines) or environmental ammonia [19, 20]. Epidemiological studies have identified co-infections with other respiratory pathogens as a major risk factor for clinical disease expression. Rodrigo et al. demonstrated complex pathogen interactions in upper respiratory tract infections of commercial free-range layers, documenting frequent co-occurrence of MG or MS with Avibacterium paragallinarum, Gallibacterium anatis, and Ornithobacterium rhinotracheale [4]. Co-infection with Cryptosporidium baileyi was shown to enhance MS colonization and aggravate tissue damage in chickens [5]. Additionally, high mortality in a commercial turkey flock was linked to co-infection of Pasteurella multocida and M. gallisepticum [35]. The presence of MG and MS in wild birds, including trafficked psittacines and free-ranging wild turkeys, indicates a sylvatic reservoir that may complicate eradication efforts in free-range systems [16, 18].

Pathogenesis and Clinical Signs

After inhalation, Mycoplasma organisms adhere to ciliated respiratory epithelial cells via specialized adhesins such as GapA and CrmA (MG) or the VlhA protein (MS) [21, 22]. Adherence is followed by ciliostasis, loss of ciliary activity, and deciliation, leading to impaired mucociliary clearance [23, 24]. The host inflammatory response is a key driver of pathology. Xu et al. elucidated a mechanism by which extracellular vesicles from Scutellaria baicalensis attenuate MG-induced inflammation via inhibition of the TRPC1–STIM1/ORAI1 calcium channel pathway, highlighting the role of calcium signaling in the inflammatory cascade [8]. Wang et al. described Enhancer of Zeste homolog 2-mediated H3K27 trimethylation silencing of LIM domain-containing protein 1, activating hippo signaling during Mycoplasma pathogenesis [29]. Transcriptomic analysis of MS exposed to chicken cells revealed upregulation of genes involved in adhesion, immune evasion, and metabolism, underscoring the pathogen’s adaptive response to the host environment [9].

Clinically, MG infection manifests as coughing, sneezing, rales, nasal discharge, and conjunctivitis, especially in young chickens [24, 25]. In layers, there is a drop in egg production and an increase in shell quality defects. Turkeys infected with MG develop swollen infraorbital sinuses and dyspnea. MS infection often presents with lameness, swollen hocks, and breast blisters due to synovitis, particularly in meat-type birds [34]. In layer flocks, MS is a recognized cause of eggshell apex abnormalities (EAA), resulting in thinning and roughening of the shell apex [7, 28]. Zhao et al. isolated and pathotyped an MS strain from a Chinese broiler farm that induced severe synovitis and high morbidity [34]. Subclinical infections are common; stress or concurrent infections are required for overt disease.

Pathology

Gross pathological lesions in MG-infected chickens include catarrhal tracheitis, airsacculitis (thickened, cloudy air sacs), and caseous exudate in the thoracic and abdominal air sacs [24, 35]. In turkeys, infraorbital sinusitis with mucopurulent or caseous exudate is characteristic. Histologically, there is lymphoid hyperplasia, mucosal thickening, and loss of cilia. For MS, typical lesions are fibrinous or purulent synovitis of the hock and stifle joints, tenosynovitis, and osteomyelitis [34]. Eggshell apex abnormalities arise from inflammatory changes in the oviduct. The severity of tracheal mucosal thickening has been proposed as a quantitative endpoint for evaluating MG vaccine immunogenicity [24]. In a 2025 study, Kulappu Arachchige et al. demonstrated that assessment of tracheal mucosal thickness using histomorphometry provides a reliable correlate of protection after vaccination [24].

Diagnostics

Accurate diagnosis of Mycoplasma infections relies on a combination of pathogen isolation, serology, and molecular methods. Culture is the gold standard but is slow and requires specialized media [25]. Taiyari et al. showed that different media formulations significantly affect the growth and antimicrobial minimum inhibitory concentrations of MG and MS, emphasizing the need for standardized protocols [25]. Serological tests include the rapid serum agglutination (RSA) test, hemagglutination inhibition (HI), and commercial enzyme-linked immunosorbent assays (ELISAs). However, cross-reactivity between MG and MS can occur, and antibody detection may be delayed.

Molecular diagnostics have become preferred due to their speed and sensitivity. Several polymerase chain reaction (PCR) methods target the mgc2 gene for MG and the vlhA gene for MS [3, 15]. The need to differentiate vaccine strains from wild-type strains has driven the development of discriminatory assays. Xin et al. developed a multiplex TaqMan real-time PCR assay for differential identification of MG wild-type and vaccine strains (e.g., ts-11, 6/85, and F-strain) [15]. For MS, Jimenez et al. reported a European ring test validating a PCR protocol that distinguishes the MS-H vaccine strain from field isolates [3]. Chen et al. described a quantitative real-time PCR approach for the same purpose [28]. Innovative isothermal amplification platforms have also emerged. Jing et al. established a high-throughput colorimetric loop-mediated isothermal amplification (LAMP) assay for MG detection, incorporating intelligent algorithm-assisted analysis for result interpretation [10]. Mayne et al. validated a field-ready colourimetric LAMP assay for MG that uses a rapid DNA extraction method suitable for on-farm deployment [13]. Hu et al. reported dual-mode recombinase-assisted amplification (RAA) combined with CRISPR/Cas12a for MS detection, achieving sensitivity comparable to real-time PCR [26]. Another group developed an RAA-CRISPR/Cas12a platform for MG detection applicable to field conditions [21]. Lateral flow immunoassays also offer rapid point-of-care diagnosis; Zidi et al. developed a triple-target gold nanoparticle lateral flow strip capable of simultaneously detecting MG, MS, and M. meleagridis [2]. For quantitative applications, Zhou et al. applied droplet digital PCR (ddPCR) for the detection and quantification of MG in duck flocks, providing absolute quantification without reliance on standard curves [30].

Vaccination Strategies

Vaccination is a cornerstone of Mycoplasma control, particularly in multi-age layer complexes and breeder operations. The primary goals are to reduce clinical disease, decrease vertical transmission, and limit bird-to-bird spread [7, 27]. Several types of [poultry mycoplasma vaccine] are available: live attenuated vaccines, inactivated (bacterin) vaccines, and recombinant vector vaccines.

Live attenuated vaccines for MG include the F-strain (moderate virulence), ts-11 (temperature-sensitive mutant), and 6/85 (low virulence). For MS, the MS-H live attenuated vaccine (temperature-sensitive) is widely used [3, 28]. F-strain vaccines offer strong protection but can revert to virulence and cause disease in turkeys. Ts-11 and 6/85 are safer but require careful administration and are less effective under high challenge pressure. Kamathewatta et al. evaluated day-old vaccination with the Vaxsafe MG304 live-attenuated vaccine and found it protected chickens from tracheal transcriptional changes induced by chronic MG infection, demonstrating the value of early vaccination [27]. However, live vaccines can interfere with serological monitoring unless discriminatory PCR assays differentiate vaccine and field strains.

Recombinant vector vaccines offer a promising alternative. A recombinant fowl pox virus (rFPV) expressing MG antigens has been developed. Hashish et al. compared vaccination programs in layer pullets using rFPV-MG versus commercially available F-strain live vaccines and reported that rFPV-MG provided comparable protection with a reduced risk of reversion to virulence [7]. Another approach uses recombinant fowl adenovirus serotype 4 (rFAdV-4) expressing MS antigens; Liu et al. demonstrated that rFAdV-4-P50 protected chickens against MS challenge [11]. A next-generation live vector vaccine based on recombinant Salmonella expressing MG and MS antigens was evaluated by Sabir et al., who showed that oral immunization induced both mucosal and systemic immune responses in chickens [22].

Bacterin (inactivated) vaccines are safe but often require adjuvants and repeated administration to induce adequate protection. They are typically used in breeders to boost maternal antibody levels, thereby reducing vertical transmission.

The route of administration significantly influences vaccine efficacy. Eye drop and spray are common for live vaccines, while injection is used for bacterins. Assessment of immunogenicity can be performed by measuring tracheal mucosal thickness, as proposed by Kulappu Arachchige et al., which correlates with protection after vaccination [24].

The following table summarizes key vaccine types and their characteristics:

DIVA (differentiating infected from vaccinated animals) capability is an important attribute. Recombinant vector vaccines and some discriminatory PCR assays facilitate DIVA strategies [7, 15].

Control Programs

Effective control of Mycoplasma infections relies on a combination of biosecurity, flock management, vaccination, and medication. The fundamental principle is the establishment and maintenance of Mycoplasma-free breeder flocks [17, 18]. This requires rigorous monitoring, including regular serological testing (RSA, HI, ELISA) and molecular screening (real-time PCR) of replacement pullets and breeders. Positive birds are culled. Hatchery biosecurity is critical to prevent vertical transmission; eggs from infected breeders should not be used for hatching [17].

In commercial layer and broiler operations where eradication is impractical, vaccination programs are implemented. The decision tree below outlines a systematic approach to implementing a Mycoplasma control program:

graph TD
    A[Flock health status], > B{Assess MG/MS status}
    B, >|Negative| C[Maintain biosecurity & monitor]
    B, >|Positive, clinical| D[Implement vaccination]
    B, >|Positive, subclinical| E{Production losses?}
    E, >|Yes| D
    E, >|No| F[Monitor & treat if triggered]
    D, > G[Select vaccine type]
    G, > H[Live attenuated]
    G, > I[Inactivated]
    G, > J[Recombinant vector]
    H, > K[Administer via spray/eye drop]
    I, > L[Administer via injection]
    J, > M[Administer per protocol]
    K, > N[Post-vaccination monitoring]
    L, > N
    M, > N
    N, > O{Discriminatory PCR positive?}
    O, >|Field strain| P[Assess vaccine failure/breakthrough]
    O, >|Vaccine strain| Q[Continue routine control]
    P, > R[Review vaccination schedule & biosecurity]
    Q, > S[Periodic re-testing]

Antimicrobial therapy is employed to treat clinical outbreaks, but the absence of a cell wall limits options to protein synthesis inhibitors (e.g., tylosin, tilmicosin, oxytetracycline, enrofloxacin). However, antimicrobial resistance is of increasing concern. Forero-Marin et al. characterized fluoroquinolone resistance genotypes in Colombian poultry Mycoplasma isolates, highlighting mutations in the gyrA and parC genes [23]. Novel antimycoplasmal agents are under investigation. Deng et al. demonstrated synergistic effects of tilmicosin and the plant alkaloid sinomenine against MS, reducing the required dose and potentially mitigating resistance development [1]. Yang et al. evaluated the pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative, APTM, against MG, showing promising activity [17]. Other natural compounds with antimycoplasmal activity include berberine, which suppresses PIK3CA-dependent inflammatory and apoptotic responses in MS-infected macrophages [31]; luteolin, which targets TatD nuclease and the MAPK pathway in MG infection [19]; and a traditional Chinese medicine preparation (Tengchuan compound mixture) that ameliorates MS-induced synovitis [33]. Additionally, cyclometalated palladium complexes have been investigated as novel antimycoplasmatic drugs [14].

An integrated control program should also address concurrent infections. Rodrigo et al. emphasized the importance of diagnosing co-pathogens (e.g., A. paragallinarum, G. anatis) in cases of upper respiratory disease, as management of these agents may reduce Mycoplasma severity [4]. Similarly, the interplay with parasitic infections such as Dermanyssus gallinae (poultry red mite) can exacerbate mycoplasmosis; integrated ectoparasite control is therefore recommended (see Dermanyssus gallinae (Poultry Red Mite): Control Strategies in Commercial Flocks).

Future Directions

Advancements in molecular diagnostics, particularly point-of-care platforms such as LAMP and CRISPR-based systems, will facilitate rapid on-farm decision-making [10, 13, 21, 26]. The development of multiplex assays that simultaneously detect MG, MS, and other respiratory pathogens will improve differential diagnosis [2, 15]. Genomic surveillance of Mycoplasma strains via whole-genome sequencing and vlhA typing will inform vaccine strain selection and track the emergence of new variants [12, 32].

Vaccine research is moving toward next-generation platforms, including virus-like particles, mRNA vaccines, and multivalent vectored vaccines [22]. DIVA-compatible vaccines combined with discriminatory PCR assays will enable vaccination without compromising surveillance programs [7, 15, 28]. Understanding host-pathogen interactions at the molecular level, such as the role of histone modifications and calcium signaling, may reveal novel therapeutic targets [8, 29]. The use of natural compounds as adjuncts or alternatives to antibiotics is a growing area of investigation, driven by the need to combat antimicrobial resistance [1, 19, 31, 33].

Conclusion

Mycoplasma infections remain a major threat to poultry health and productivity worldwide. Successful control requires a multifaceted approach combining rigorous biosecurity, active surveillance using advanced molecular diagnostics, strategic vaccination with appropriately selected [poultry mycoplasma vaccine] types, and judicious antimicrobial use. The advent of recombinant vector vaccines and point-of-care diagnostic tools offers new opportunities for disease management. Continued research into pathogenesis, immune responses, and novel therapeutics will further refine control programs.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Deng B, Wang X, Li M, et al. A novel therapeutic strategy for Mycoplasma synoviae infection: Elucidating the synergistic effects and underlying mechanisms of Tilmicosin and Sinomenine. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42308745/

[2] Zidi S, Yacoub E, Chniba I, et al. Development and validation of a rapid triple-target gold nanoparticle lateral flow immunoassay for detection of three avian mycoplasmas immunochromatographic strip test for avian mycoplasma detection. BMC Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42288724/

[3] Jimenez CM, Kreizinger Z, Gyuranecz M, et al. European ring test on the differentiation of wild-type Mycoplasma synoviae and the MS-H vaccine strains in clinical samples. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42235157/

[4] Rodrigo CH, Kulappu Arachchige SN, Bushell RN, et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42190304/

[5] Zhang Y, Li Y, Wang Z, et al. Cryptosporidium baileyi and Mycoplasma synoviae co-infection enhances M. synoviae colonization and aggravates tissue damage in chickens. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42158394/

[6] Fan P, Liu Z, Xu Y, et al. Strain-specific detection of Mycoplasma gallisepticum: A duplex qPCR assay for vaccine efficacy and infection surveillance. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42139893/

[7] Hashish A, Chaves M, Osemeke O, et al. Evaluation of Vaccination Programs in Layer Pullets Using Recombinant Fowl-Pox Mycoplasma gallisepticum Vaccine in Comparison to Commercially Available F-Strain Live Vaccines. Avian Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41973009/

[8] Xu F, Bao L, Yao Y, et al. Mechanism of Scutellaria baicalensis extracellular vesicles in attenuating Mycoplasma gallisepticum-induced inflammation via TRPC1 - STIM1/ORAI1 channel inhibition. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41905072/

[9] Si D, Bao S, Guo L, et al. Transcriptome landscape of Mycoplasma synoviae when exposed to chicken cells. BMC Genomics. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41904433/

[10] Jing W, Cai Q, Liang Y, et al. High-throughput colorimetric LAMP detection of Mycoplasma gallisepticum with intelligent algorithm-assisted analysis. Anal Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41891257/

[11] Liu Y, Li W, Li G, et al. Protection of chickens against M. synoviae infection by vaccination with a recombinant fowl adenovirus 4-P50. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41887300/

[12] Stefani E, Morales-Arce AY, Nai G, et al. Molecular typing of Mycoplasma synoviae in industrial and backyard poultry: a 14-year study in Italy. Appl Environ Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41817199/

[13] Mayne R, Pant SD, Huang J, et al. A field-ready colourimetric LAMP assay for detection of Mycoplasma gallisepticum using rapid DNA extraction. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41785617/

[14] Vishnyakov IE, Plekhanov AY, Goodkov AV, et al. Cyclometalated palladium complexes as promising antimycoplasmatic drugs. Naunyn Schmiedebergs Arch Pharmacol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41711837/

[15] Xin J, Zhang J, Liang S, et al. A multiplex TaqMan real-time PCR assay for differential identification of wild-type and vaccine strains of Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41702344/

[16] Edge AC, Moorman CE, Pacifici K, et al. Regional Pathogen Surveillance of Free-Ranging Wild Turkeys (Meleagris gallopavo) in North Carolina, USA. J Wildl Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41667058/

[17] Yang W, Ding H, Ma X, et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41650639/

[18] Marín-Villa J, Alzate-Vargas JF, Ramírez TG, et al. Serological evidence and risk factors of Mycoplasma gallisepticum and Mycoplasma synoviae exposure in trafficked parrots and macaws in Colombia. Open Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41630737/

[19] Liu W, Wang S, Hu J, et al. Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41548475/

[20] Sudnick MC, Sauer EL, DuRant SE. Prior Infection Induces Long-Lasting Partial Immunity to Reduce Transmission within Flocks in an Avian Host-Pathogen System. Ecol Evol Physiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41529280/

[21] Hu Q, Zhang R, Liu J, et al. A rapid and field-deployable RAA-CRISPR/Cas12a platform for detection of Mycoplasma gallisepticum in poultry. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41526975/

[22] Sabir R, Liu M, Saeed HA, et al. Next-generation live vector vaccine targeting Mycoplasma synoviae and Mycoplasma gallisepticum via recombinant Salmonella. Vaccine. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41518971/

[23] Forero-Marin S, Gomez AP, Beltran-Leon M, et al. A first look into the genomic characterization and fluoroquinolone resistance genotypes of Mycoplasma spp. in Colombian poultry. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41401692/

[24] Kulappu Arachchige SN, Abeykoon AMH, Stevenson MA, et al. Assessment of tracheal mucosal thicknesses is a preferable method for evaluation of the immunogenicity of Mycoplasma gallisepticum vaccines in poultry. Vaccine. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41365127/

[25] Taiyari H, Abu J, Zakaria Z, et al. Different media affect the growth and antimicrobial minimum inhibitory concentrations of Mycoplasma gallisepticum and Mycoplasma synoviae. J Microbiol Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41319922/

[26] Hu Q, Liu J, Zhang W, et al. Rapid nucleic acid detection of Mycoplasma synoviae using dual-mode RAA-CRISPR/Cas12a system. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41270550/

[27] Kamathewatta KI, Kanci Condello A, Ekanayake D, et al. Day-old